SPONSORED CONTENT
Join 340B industry experts Ted Slafsky, Publisher and CEO of 340B Report, and AJ Rivosecchi, PharmD, Product Director at Bluesight, for a presentation and Q&A session on the recent, unprecedented changes to the 340B program.
*Please note that this event is limited to 340B covered entities only.
As covered entities start to plan for the transition from upfront 340B discounts to a rebate model for key medications, hospitals and other 340B providers face significant cash flow challenges, operational complexity, and new compliance concerns. This timely presentation will provide critical insights into:
- Recent legal challenges to the rebate pilot, including the lawsuit filed by hospital groups seeking to block implementation
- Advocacy efforts to try to stop rebates or mitigate impact
- Early observations on the claims submission and rebate process and tips for success
- The operational and financial impact of purchasing at WAC pricing while awaiting rebates and the best ways to track and prepare for this
- How to navigate the dual-program complexity between 340B rebates and IRA Maximum Fair Prices for the same 10 drugs
- Practical strategies for maintaining 100% audit compliance while efficiently managing the rebate submission process
Whether you’re concerned about cash flow management, compliance validation, or optimizing your approach for the 10 pilot drugs, this webinar will provide actionable guidance to help your organization maintain savings while adapting to these regulatory changes.
